Jim Simons
NKTR icon

Jim Simons’s Nektar Therapeutics NKTR Stock Holding History

Jim Simons’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,781
Closed -$3.01M – 3495
2026
Q1 		$3.01M Sell
41,781
-131,100
-76% -$7.46M ﹤0.01% 1661
2025
Q4 		$7.31M Sell
172,881
-105,660
-38% -$5.91M 0.01% 1081
2025
Q3 		$15.8M Buy
278,541
+31,481
+13% +$1.04M 0.02% 849
2025
Q2 		$6.38M Sell
247,060
-66,392
-21% -$745K 0.01% 1363
2025
Q1 		$3.2M Buy
313,452
+52,733
+20% +$689K ﹤0.01% 1707
2024
Q4 		$3.64M Buy
260,719
+38,877
+18% +$686K 0.01% 1646
2024
Q3 		$4.33M Buy
221,842
+920
+0.4% +$17.5K 0.01% 1532
2024
Q2 		$4.11M Sell
220,922
-87,123
-28% -$1.84M 0.01% 1434
2024
Q1 		$4.32M Sell
308,045
-46,987
-13% -$492K 0.01% 1506
2023
Q4 		$3.01M Buy
355,032
+121,253
+52% +$918K ﹤0.01% 1690
2023
Q3 		$2.09M Sell
233,779
-39,000
-14% -$375K ﹤0.01% 1833
2023
Q2 		$2.35M Buy
272,779
+72,533
+36% +$773K ﹤0.01% 1890
2023
Q1 		$2.11M Buy
200,246
+192,439
+2,465% +$5.82M ﹤0.01% 1992
2022
Q4 		$265K Buy
+7,807
New +$378K ﹤0.01% 3282
2019
Q3 		– Sell
-21,803
Closed -$11.6M – 3610
2019
Q2 		$11.6M Buy
21,803
+8,106
+59% +$4.06M 0.01% 1302
2019
Q1 		$6.9M Sell
13,697
-13,100
-49% -$7.76M 0.01% 1604
2018
Q4 		$13.2M Buy
26,797
+22,207
+484% +$13.4M 0.01% 1149
2018
Q3 		$4.2M Buy
4,590
+2,667
+139% +$2.28M ﹤0.01% 1914
2018
Q2 		$1.41M Buy
+1,923
New +$2.22M ﹤0.01% 2450
2018
Q1 		– Sell
-6,123
Closed -$5.48M – 3504
2017
Q4 		$5.48M Buy
+6,123
New +$3.62M 0.01% 1747
2015
Q2 		– Sell
-37,870
Closed -$6.25M – 3315
2015
Q1 		$6.25M Buy
37,870
+9,060
+31% +$1.86M 0.01% 1222
2014
Q4 		$6.7M Buy
+28,810
New +$6.16M 0.02% 1106

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jim Simons's NKTR Position: Q2 2026 in Review

Jim Simons sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 41,781 shares — an estimated $3.01M sold.

Jim Simons first reported a position in NKTR in Q4 2014 and held it in 22 quarters. The position peaked at $15.8M in Q3 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Jim Simons reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jim Simons sold 41,781 Nektar Therapeutics shares in Q2 2026, an estimated $3.01M.
  • Jim Simons first reported a position in Nektar Therapeutics in Q4 2014 and held it in 22 quarters.
  • Jim Simons's Nektar Therapeutics position peaked at $15.8M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.